Patents by Inventor Bruce L. Daugherty

Bruce L. Daugherty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for reducing the immunogenicity of antibody variable domains
    Publication number: 20040253645
    Abstract: A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.
    Type: Application
    Filed: July 2, 2004
    Publication date: December 16, 2004
    Inventors: Bruce L. Daugherty, George E. Mark, Eduardo A. Padlan
  • Method for reducing the immunogenicity of antibody variable domains
    Patent number: 6797492
    Abstract: A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: September 28, 2004
    Assignees: Merck & Co., Inc., United States of America
    Inventors: Bruce L. Daugherty, George E. Mark, III, Eduardo A. Padlan
  • Eosinophil eotaxin receptor
    Publication number: 20020192214
    Abstract: The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human &bgr;-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.
    Type: Application
    Filed: August 6, 2001
    Publication date: December 19, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Bruce L. Daugherty, Julie A. Demartino, Salvatore J. Siciliano, Martin S. Springer
  • Method for reducing the immunogenicity of antibody variable domains
    Publication number: 20020034765
    Abstract: A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.
    Type: Application
    Filed: March 16, 2001
    Publication date: March 21, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Bruce L. Daugherty, George E. Mark, Eduardo A. Padlan
  • Eosinophil eotaxin receptor
    Patent number: 6271347
    Abstract: The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human &bgr;-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.
    Type: Grant
    Filed: April 24, 1997
    Date of Patent: August 7, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Bruce L. Daugherty, Julie A. Demartino, Salvatore J. Siciliano, Martin S. Springer
  • Vampire bat salivary plasminogen activators
    Patent number: 5830849
    Abstract: Purified plasminogen activator proteins obtained or derived from the vampire bat Desmodus rotundus saliva and salivary glands, methods for purifying the proteins, DNA sequences encoding these proteins, means for producing them using recombinant DNA technology, pharmaceutical compositions comprising these proteins and methods of treatment utilizing these proteins are provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 3, 1998
    Assignee: Schering Aktiengesellschaft
    Inventors: Richard A. F. Dixon, Stephen J. Gardell, Le Thi Duong, Paul A. Friedman, John W. Jacobs, George E. Mark, Bruce L. Daugherty